All are activated by insulin except?
ATP is consumed at which of the following steps of glycolysis?
Glycogen synthase is activated by?
What coenzyme is required by gulonate dehydrogenase for its activity?
What is the rate-controlling enzyme of fatty acid synthesis?
Which of the following enzymes uses citrate in fatty acid synthesis?
Which of the following is an ω-6 fatty acid?
Apo-E deficiency is seen in which of the following conditions?
Which of the following is a lipotropic factor?
Which enzyme deficiency is responsible for Hyperammonemia type-1?
NEET-PG 2012 - Biochemistry NEET-PG Practice Questions and MCQs
Question 121: All are activated by insulin except?
- A. Lipoprotein lipase
- B. Pyruvate kinase
- C. Acetyl-CoA carboxylase
- D. Hormone sensitive lipase (Correct Answer)
Explanation: ***Hormone sensitive lipase*** - **Insulin** is an **anabolic hormone** that promotes energy storage; it **inhibits** hormone-sensitive lipase (HSL) activity which is responsible for **fat breakdown (lipolysis)**. - When insulin levels are high, the body stores fat rather than breaks it down, thus **decreasing** HSL activity. *Lipoprotein lipase* - **Insulin activates lipoprotein lipase (LPL)**, an enzyme that breaks down triglycerides in **chylomicrons** and **VLDL** into fatty acids for storage in adipose tissue. - This activation promotes the uptake of fatty acids into fat cells, aligning with insulin's role in **energy storage**. *Pyruvate kinase* - **Insulin activates pyruvate kinase** in glycolysis, promoting the conversion of **phosphoenolpyruvate to pyruvate**. - This enzyme's activation enhances glucose utilization and energy production following a meal when insulin levels are high. *Acetyl-CoA carboxylase* - **Insulin activates acetyl-CoA carboxylase (ACC)**, the **rate-limiting enzyme in fatty acid synthesis**. - Activation of ACC leads to the production of **malonyl-CoA**, which commits acetyl-CoA to fatty acid synthesis, storing excess energy as fat.
Question 122: ATP is consumed at which of the following steps of glycolysis?
- A. Pyruvate kinase
- B. Isomerase
- C. Hexokinase (Correct Answer)
- D. Enolase
Explanation: ***Hexokinase*** - This enzyme catalyzes the **first step of glycolysis**, the phosphorylation of glucose to **glucose-6-phosphate**, which requires the consumption of one molecule of **ATP**. - ATP is hydrolyzed to **ADP**, providing the necessary phosphate group and energy for this irreversible reaction. - Note: Hexokinase is one of **two ATP-consuming steps** in glycolysis (the other being phosphofructokinase in step 3). *Pyruvate kinase* - This enzyme catalyzes the **final step of glycolysis**, converting **phosphoenolpyruvate (PEP)** to pyruvate. - This reaction involves the **production of ATP** from ADP, not its consumption, as it's one of the substrate-level phosphorylation steps. *Isomerase* - Isomerase enzymes, like phosphoglucose isomerase, convert one isomer to another (e.g., glucose-6-phosphate to fructose-6-phosphate). - These reactions generally involve an **internal rearrangement of atoms** and do not directly consume or produce ATP. *Enolase* - Enolase catalyzes the reversible conversion of **2-phosphoglycerate to phosphoenolpyruvate (PEP)**, releasing a molecule of water. - This step occurs before the ATP-generating step catalyzed by pyruvate kinase and **does not consume or produce ATP**.
Question 123: Glycogen synthase is activated by?
- A. Insulin (Correct Answer)
- B. Glucagon
- C. AMP
- D. Epinephrine
Explanation: **Insulin** - Insulin activates **glycogen synthase** through a signaling cascade that dephosphorylates the enzyme, shifting it to its active form (glycogen synthase a). - This activation promotes **glycogen synthesis** in the liver and muscles, lowering blood glucose levels. *Glucagon* - **Glucagon** primarily acts to increase blood glucose levels by activating **glycogen phosphorylase** and inhibiting glycogen synthase. - It promotes the breakdown of glycogen (glycogenolysis) rather than its synthesis. *Epinephrine* - **Epinephrine** (adrenaline) also promotes **glycogenolysis** (glycogen breakdown) by activating glycogen phosphorylase. - Its main role is to provide rapid energy during stress, not to store glucose as glycogen. *AMP* - **AMP** (adenosine monophosphate) is a key allosteric activator of **AMP-activated protein kinase (AMPK)**, which phosphorylates and inactivates glycogen synthase. - High AMP levels signal a low energy state, prompting ATP-generating pathways like glycogenolysis, not glycogen synthesis.
Question 124: What coenzyme is required by gulonate dehydrogenase for its activity?
- A. FAD
- B. FMN
- C. NADP
- D. NAD (Correct Answer)
Explanation: ***NAD*** - **Gulonate dehydrogenase** is an enzyme involved in the **uronic acid pathway**, specifically in the conversion of **L-gulonate to D-xylulose**. - This reaction is an **NAD-dependent oxidation**, meaning **NAD** acts as the electron acceptor, being reduced to **NADH**. *NADP* - **NADP** (nicotinamide adenine dinucleotide phosphate) is primarily involved in **anabolic pathways** like **fatty acid synthesis** and the **pentose phosphate pathway**, often in reduction reactions where it is converted to **NADPH**. - While structurally similar to NAD, it is generally not the direct coenzyme for gulonate dehydrogenase. *FAD* - **FAD** (flavin adenine dinucleotide) is a coenzyme derived from **riboflavin** (vitamin B2) and is typically involved in **redox reactions** where it repeatedly accepts and donates electrons, often in dehydrogenase reactions involving **carbon-carbon double bonds**. - Enzymes like **succinate dehydrogenase** (in the citric acid cycle) or acyl-CoA dehydrogenase (in fatty acid oxidation) utilize FAD, but not gulonate dehydrogenase. *FMN* - **FMN** (flavin mononucleotide) is another coenzyme derived from **riboflavin** and serves as a prosthetic group in various **flavoproteins**, often facilitating **single-electron transfers**. - It is frequently found in complexes like **NADH dehydrogenase** (Complex I of the electron transport chain) but is not the required coenzyme for gulonate dehydrogenase activity.
Question 125: What is the rate-controlling enzyme of fatty acid synthesis?
- A. Thioesterase
- B. Transacetylase
- C. Acetyl-CoA carboxylase (Correct Answer)
- D. Ketoacyl synthase
Explanation: ***Acetyl-CoA carboxylase*** - **Acetyl-CoA carboxylase (ACC)** catalyzes the committed step in fatty acid synthesis, converting **acetyl-CoA** to **malonyl-CoA**. - This enzyme is subject to both allosteric regulation (e.g., activation by **citrate** and inhibition by **long-chain fatty acyl-CoA**) and hormonal regulation (e.g., phosphorylation by glucagon and dephosphorylation by insulin). *Thioesterase* - **Thioesterase** is the enzyme responsible for releasing the completed fatty acid chain from the **fatty acid synthase complex**. - While essential for the termination of synthesis, it does not regulate the initiation or overall rate of the pathway. *Transacetylase* - **Transacetylase** (specifically, acetyl-CoA-ACP transacetylase and malonyl-CoA-ACP transacetylase) is involved in transferring acetyl and malonyl groups to the **acyl carrier protein (ACP)** within the fatty acid synthesis complex. - This is an intermediary step, but not the primary **rate-controlling** or committed step. *Ketoacyl synthase* - **Ketoacyl synthase (or β-ketoacyl-ACP synthase)** is responsible for condensing the growing acyl chain with malonyl-ACP, leading to the formation of a **β-ketoacyl-ACP**. - This is a crucial chain elongation step within the fatty acid synthase complex, but not the enzyme that controls the overall commitment to fatty acid synthesis.
Question 126: Which of the following enzymes uses citrate in fatty acid synthesis?
- A. Aconitase
- B. ATP citrate lyase (Correct Answer)
- C. Malic enzyme
- D. Citrate synthase
Explanation: ***ATP citrate lyase*** - This enzyme is crucial for fatty acid synthesis, as it cleaves **citrate** in the cytoplasm to generate **acetyl-CoA** and oxaloacetate. - The acetyl-CoA produced is then used as the primary building block for **fatty acid synthesis**. *Aconitase* - This enzyme isomerizes **citrate** to isocitrate within the **Krebs cycle** (TCA cycle) in the mitochondria. - It does not directly participate in the cytosolic pathway of fatty acid synthesis. *Citrate synthase* - This enzyme synthesizes **citrate** from acetyl-CoA and oxaloacetate, initiating the **Krebs cycle** in the mitochondrial matrix. - It is involved in citrate formation, not its utilization for fatty acid synthesis in the cytoplasm. *Malic enzyme* - This enzyme converts **malate** to pyruvate, generating **NADPH** in the cytoplasm. - While NADPH is essential for fatty acid synthesis, malic enzyme does not directly use citrate.
Question 127: Which of the following is an ω-6 fatty acid?
- A. Cervonic acid
- B. Linoleic acid (Correct Answer)
- C. Alpha linolenic acid
- D. Elaidic acid
Explanation: ***Linoleic acid*** - **Linoleic acid** (LA), an 18-carbon fatty acid with two double bonds (18:2), is classified as an **ω-6 fatty acid** because its first double bond is located at the sixth carbon atom from the methyl end of the fatty acid chain. - It is an **essential fatty acid** that must be obtained through diet, serving as a precursor for other ω-6 fatty acids like arachidonic acid. *Cervonic acid* - **Cervonic acid** is another name for **docosahexaenoic acid (DHA)**, which is an **ω-3 fatty acid** (22:6). - Its first double bond is located at the third carbon from the methyl end. *Alpha linolenic acid* - **Alpha-linolenic acid** (ALA) is an **ω-3 fatty acid** (18:3). - Its first double bond is located at the third carbon atom from the methyl end. *Elaidic acid* - **Elaidic acid** is a **trans fatty acid** (18:1 trans-9). - It is classified as an **ω-9 fatty acid** due to the position of its double bond, but its trans configuration is the primary distinguishing feature.
Question 128: Apo-E deficiency is seen in which of the following conditions?
- A. Type II hyperlipoproteinemia
- B. Type III hyperlipoproteinemia (Correct Answer)
- C. Type I hyperlipoproteinemia
- D. Type IV hyperlipoproteinemia
Explanation: ***Type III hyperlipoproteinemia*** - This condition, also known as **familial dysbetalipoproteinemia** or **broad beta disease**, is characterized by a deficiency or abnormal function of **apolipoprotein E (apoE)**. - The deficiency in functional apoE impairs the clearance of **chylomicron remnants** and **intermediate-density lipoproteins (IDLs)** from the blood. *Type II hyperlipoproteinemia* - This condition primarily involves elevated **LDL cholesterol** and is often due to defects in the **LDL receptor** or mutations in **apoB-100**, not apoE deficiency. - It does not directly involve the impaired clearance of chylomicron remnants or IDLs. *Type I hyperlipoproteinemia* - Also known as **familial chylomicronemia syndrome**, this condition is characterized by severe elevation of **chylomicrons** and **triglycerides**. - It is caused by a deficiency of **lipoprotein lipase (LPL)** or its cofactor **apoC-II**, not apoE. *Type IV hyperlipoproteinemia* - This condition, also known as **familial hypertriglyceridemia**, is characterized by abnormally high levels of **very-low-density lipoproteins (VLDL)** and **triglycerides**. - It is typically caused by increased VLDL production or impaired VLDL clearance, but not directly due to an apoE deficiency.
Question 129: Which of the following is a lipotropic factor?
- A. Sphingomyelin
- B. Histidine
- C. Bilirubin
- D. Methionine (Correct Answer)
Explanation: ***Methionine*** - **Methionine** is an essential amino acid that serves as a precursor for **choline** and **creatine**, both of which play crucial roles in lipid metabolism and transport. - Lipotropic factors prevent or reverse the accumulation of **fat in the liver** by promoting the synthesis of **lipoproteins**, which package and transport fats from the liver to other tissues. *Sphingomyelin* - **Sphingomyelin** is a type of **sphingolipid**, a component of cell membranes and myelin sheaths, but it does not directly act as a lipotropic factor to prevent fatty liver. - While it's involved in cellular signaling and membrane structure, it does not directly facilitate the metabolism or transport of **hepatic triglycerides** in the same way as lipotropic agents. *Histidine* - **Histidine** is an essential amino acid involved in protein synthesis and the production of **histamine**, but it is not considered a primary lipotropic factor. - Its main roles are in **immune response** and **neurotransmission**, not in preventing fat accumulation in the liver. *Bilirubin* - **Bilirubin** is a waste product from the breakdown of **heme**, primarily from red blood cells. It is excreted by the liver. - It is known for its **antioxidant properties** but does not play a direct role as a lipotropic factor in lipid metabolism or in preventing **fatty liver**.
Question 130: Which enzyme deficiency is responsible for Hyperammonemia type-1?
- A. Arginase deficiency
- B. Arginosuccinate lyase deficiency
- C. Arginosuccinate synthase deficiency
- D. Carbamoyl phosphate synthetase I (CPS-1) deficiency (Correct Answer)
Explanation: ***Carbamoyl phosphate synthetase I (CPS-1) deficiency*** - This enzyme deficiency is classified as **Hyperammonemia type-1**, or **CPS1 deficiency**, and results in the inability to initiate the urea cycle. - **CPS-1** catalyzes the first committed step of the urea cycle, combining ammonia and bicarbonate to form carbamoyl phosphate. *Arginase deficiency* - This deficiency causes **Hyperargininemia**, which is a disorder of the urea cycle distinct from Hyperammonemia type-1. - Arginase is involved in the final step of the urea cycle, converting arginine to urea and ornithine. *Arginosuccinate lyase deficiency* - This deficiency leads to **Argininosuccinic aciduria**, another urea cycle disorder. - **Arginosuccinate lyase** is responsible for breaking down argininosuccinate into arginine and fumarate. *Arginosuccinate synthase deficiency* - This deficiency causes **Citrullinemia type 1**, a metabolic disorder characterized by high levels of citrulline and ammonia. - **Arginosuccinate synthase** catalyzes the condensation of citrulline and aspartate to form argininosuccinate.